Omeros (NASDAQ:OMER) Shares Gap Up After Earnings Beat

Omeros Corporation (NASDAQ:OMER) gapped up prior to trading on Wednesday after the company announced better than expected quarterly earnings. The stock had previously closed at $10.56, but opened at $11.32. Omeros shares last traded at $12.1660, with a volume of 1,088,476 shares.

The biopharmaceutical company reported $3.14 EPS for the quarter, topping the consensus estimate of ($0.55) by $3.69.

Key Omeros News

Here are the key news stories impacting Omeros this week:

• Positive Sentiment: Q4 results beat expectations driven by a one‑time Novo Nordisk deal that materially lifted EPS; investors have been upbeat about the earnings surprise and the deal’s cash impact. Omeros Corporation Q4 2025 Earnings Call Summary
• Positive Sentiment: Management says YARTEMLEA is expected to be financially self‑sustaining in 2026 and the company is targeting positive cash flow in 2027 — a clear longer‑term de‑risking catalyst if execution continues. Omeros expects YARTEMLEA to be financially self-sustaining in 2026…
• Positive Sentiment: Unusually large call‑option buying was reported ahead of and around the earnings period, suggesting some traders expect further upside or continued volatility. (Market options flow reported 7,487 calls bought vs a typical ~4,876.)
• Neutral Sentiment: Full earnings‑call transcripts and summaries provide operational context (deal terms, launch timelines, FDA updates) but contain mixed detail; these are useful for assessing whether recent gains are sustainable. Earnings Call Transcript
• Neutral Sentiment: Analyst pieces and bullish case writeups frame a potential upside ahead of Q1 commercial updates, but they also note execution and commercialization milestones that must be met. Making The Bull Case On Q4 Earnings
• Negative Sentiment: Some analyst commentary was mixed, highlighting that the EPS beat was boosted by a one‑time windfall and that forward commercial execution and sustainable revenue proof points will determine longer‑term valuation — potentially tempering enthusiasm. Analysts Offer Insights on Healthcare Companies
• Negative Sentiment: After a post‑earnings after‑hours pop tied to the Novo deal and launch optimism, some investors appear to be taking profits or reassessing valuation, which likely contributed to intraday selling pressure. OMER stock surges 5% after-hours

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. HC Wainwright increased their target price on Omeros from $20.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday, January 8th. Wall Street Zen cut shares of Omeros from a “hold” rating to a “sell” rating in a research note on Saturday, January 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Omeros in a research report on Thursday, January 22nd. Finally, D. Boral Capital reissued a “buy” rating and set a $36.00 price objective on shares of Omeros in a research note on Tuesday, January 27th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $40.33.

Insider Transactions at Omeros

In other Omeros news, CAO David J. Borges sold 30,000 shares of the company’s stock in a transaction on Tuesday, January 13th. The stock was sold at an average price of $12.31, for a total transaction of $369,300.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 12.90% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its holdings in Omeros by 19.9% in the fourth quarter. Vanguard Group Inc. now owns 4,013,315 shares of the biopharmaceutical company’s stock worth $68,929,000 after purchasing an additional 666,357 shares in the last quarter. UBS Group AG lifted its position in Omeros by 213.5% during the fourth quarter. UBS Group AG now owns 2,222,982 shares of the biopharmaceutical company’s stock valued at $38,180,000 after acquiring an additional 1,513,893 shares during the last quarter. Geode Capital Management LLC boosted its stake in Omeros by 6.3% in the fourth quarter. Geode Capital Management LLC now owns 1,631,350 shares of the biopharmaceutical company’s stock valued at $28,026,000 after acquiring an additional 95,979 shares in the last quarter. State Street Corp grew its holdings in Omeros by 26.9% in the fourth quarter. State Street Corp now owns 1,573,526 shares of the biopharmaceutical company’s stock worth $27,025,000 after purchasing an additional 333,798 shares during the last quarter. Finally, Two Sigma Investments LP grew its holdings in Omeros by 39.3% in the third quarter. Two Sigma Investments LP now owns 933,314 shares of the biopharmaceutical company’s stock worth $3,827,000 after purchasing an additional 263,095 shares during the last quarter. 48.79% of the stock is owned by institutional investors.

Omeros Stock Down 9.8%

The company has a market capitalization of $784.80 million, a PE ratio of -21.80 and a beta of 2.53. The business has a 50 day simple moving average of $11.38 and a 200 day simple moving average of $9.78.

About Omeros

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.